RT Journal Article
SR Electronic
T1 Antibody testing for COVID-19: A report from the National COVID Scientific Advisory Panel
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.04.15.20066407
DO 10.1101/2020.04.15.20066407
A1 Adams, Emily
A1 Ainsworth, Mark
A1 Anand, Rekha
A1 Andersson, Monique I
A1 Auckland, Kathryn
A1 Baillie, J Kenneth
A1 Barnes, Eleanor
A1 Beer, Sally
A1 Bell, John I
A1 Berry, Tamsin
A1 Bibi, Sagida
A1 Carroll, Miles
A1 Chinnakannan, Senthil K
A1 Clutterbuck, Elizabeth
A1 Cornall, Richard J
A1 Crook, Derrick W
A1 de Silva, Thushan
A1 Dejnirattisai, Wanwisa
A1 Dingle, Kate E
A1 Dold, Christina
A1 Espinosa, Alexis
A1 Eyre, David W
A1 Farmer, Helen
A1 Mendoza, Maria Fernandez
A1 Georgiou, Dominique
A1 Hoosdally, Sarah J
A1 Hunter, Alistair
A1 Jeffery, Katie
A1 Klenerman, Paul
A1 Knight, Julian
A1 Knowles, Clarice
A1 Kwok, Andrew J
A1 Leuschner, Ullrich
A1 Levin, Robert
A1 Liu, Chang
A1 López-Camacho, César
A1 Martinez, Jose
A1 Matthews, Philippa C
A1 McGivern, Hannah
A1 Mentzer, Alexander J
A1 Milton, Jonathan
A1 Mongkolsapaya, Juthathip
A1 Moore, Shona C
A1 Oliveira, Marta S
A1 Pereira, Fiona
A1 Perez, Elena
A1 Peto, Timothy
A1 Ploeg, Rutger J
A1 Pollard, Andrew
A1 Prince, Tessa
A1 Roberts, David J
A1 Rudkin, Justine K
A1 Sanchez, Veronica
A1 Screaton, Gavin R
A1 Semple, Malcolm G
A1 Skelly, Donal T
A1 Slon-Campos, Jose
A1 Smith, Elliot Nathan
A1 Sobrinodiaz, Alberto
A1 Staves, Julie
A1 Stuart, David I
A1 Supasa, Piyada
A1 Surik, Tomas
A1 Thraves, Hannah
A1 Tsang, Pat
A1 Turtle, Lance
A1 Walker, A Sarah
A1 Wang, Beibei
A1 Washington, Charlotte
A1 Watkins, Nicholas
A1 Whitehouse, James
YR 2020
UL http://medrxiv.org/content/early/2020/05/07/2020.04.15.20066407.abstract
AB Objectives The COVID-19 pandemic caused >1 million infections during January-March 2020. There is an urgent need for reliable antibody detection approaches to support diagnosis, vaccine development, safe release of individuals from quarantine, and population lock-down exit strategies. We set out to evaluate the performance of ELISA and lateral flow immunoassay (LFIA) devices.Design We tested plasma for COVID (SARS-CoV-2) IgM and IgG antibodies by ELISA and using nine different LFIA devices.Setting We performed laboratory work at the University of Oxford.Participants We used a panel of plasma samples from individuals who have had confirmed COVID infection based on a PCR result (n=40), and pre-pandemic negative control samples banked in the UK prior to December-2019 (n=142).Main outcome measures We recorded optical density results from ELISA experiments and positive/negative/invalid results from LFIA devices.Results ELISA detected IgM or IgG in 34/40 individuals with a confirmed history of COVID infection (sensitivity 85%, 95%CI 70-94%), vs. 0/50 pre-pandemic controls (specificity 100% [95%CI 93-100%]). IgG levels were detected in 31/31 COVID-positive individuals tested ≥10 days after symptom onset (sensitivity 100%, 95%CI 89-100%). IgG titres rose during the 3 weeks post symptom onset and began to fall by 8 weeks, but remained above the detection threshold. Point estimates for the sensitivity of LFIA devices ranged from 55-70% versus RT-PCR and 65-85% versus ELISA, with specificity 95-100% and 93-100% respectively. Within the limits of the study size, the performance of most LFIA devices was similar.Conclusions Currently available commercial LFIA devices do not perform sufficiently well for individual patient applications. ELISA can be calibrated to be specific for detecting and quantifying SARS-CoV-2 IgM and IgG and is highly sensitive for IgG from 10 days following first symptoms.Competing Interest StatementRC reports personal fees and other from MIROBIO Ltd, outside the submitted work. DWE reports personal fees from Gilead, outside the submitted work. SH reports grants from NIHR, during the conduct of the study. AJP reports grants from NIHR Oxford Biomedical Research Centre, outside the submitted work; and AJP is Chair of UK Dept. Health and Social Care’s (DHSC) Joint Committee on Vaccination & Immunisation (JCVI) and is a member of the WHO’s SAGE. The views expressed in this article do not necessarily represent the views of DHSC, JCVI, NIHR or WHO. MGS reports grants from National Institute of Health Research, grants from Medical Research Council UK, grants from Health Protection Research Unit in Emerging & Zoonotic Infections, University of Liverpool, during the conduct of the study; other from Integrum Scientific LLC, Greensboro, NC, USA, outside the submitted work. ASW reports grants from NIHR, during the conduct of the study. No other author has a conflict of interest to declare.Funding StatementThis study was supported by the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre, the UK Government Department of Health and Social Care and and grants from NIHR [award CO-CIN-01] and the Medical Research Council [grant MC_PC_19059]. DC, TEAP and ASW are supported by the National Institute for Health Research (NIHR) Health Protection Research Unit in Healthcare Associated Infections and Antimicrobial Resistance at the University of Oxford in partnership with Public Health England (NIHR200915). Blood donor and QUOD samples were provided with support from NHS Blood and Transplant and the Medical Research Council UK. SKC is supported by Medical Research Council UK. TdS is funded by a Wellcome Trust Intermediate Clinical Fellowship (110058/Z/15/Z). DWE is a Robertson Foundation Fellow and NIHR Oxford BRC Senior Research Fellow. PM is a Wellcome Trust Clinical Research Fellow (110110/Z/15/Z) and NIHR Oxford BRC Senior Research Fellow. AM, PK, SCM, TPr, MGS and LT are supported by NIHR Health Protection Research Unit in Emerging and Zoonotic Infections (HPRU-EZI) at University of Liverpool in partnership with Public Health England (PHE), in collaboration with the University of Oxford and Liverpool School of Tropical Medicine (award number NIHR200907). EB, PK, AJP and ASW are NIHR Senior Investigators. PK (WT109965/MA) and GRS (095541/A/11/Z) are Wellcome Trust Senior Investigators. JR is supported by a Sir Henry Dale Fellowship, jointly funded by the Wellcome Trust and the Royal Society (Grant 101237/Z/13/B). The views expressed are the author(s) and are not necessarily those of the NHS, the NIHR, the UK Department of Health and Social Care, the MRC or PHE.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesResults generated for all samples and relevant metadata is provided in Table S7.